The Sjogren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome
Open Access
- 29 April 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 47 (8), 1193-1198
- https://doi.org/10.1093/rheumatology/ken164
Abstract
Objective. To validate a tool for assessment of accumulated damage in patients with Primary SS (PSS). Methods. Of the total 114 patients fulfilling American–European Consensus Group (AECG) criteria for PSS 104 were included in the study and assessed by rheumatologists at T (time) = 0 months and T = 12 months. On each occasion, damage and activity data, and autoantibody status were collected. SF-36 and Profile of Fatigue and Discomfort-Sicca Symptoms Inventory (PROFAD-SSI) questionnaires were completed. Cross-sectional analysis of this data was subject to a process of expert validation by 11 ophthalmologists, 14 oral medicine specialists and 8 rheumatologists. Items were removed from the index if ≥ 50% of respondents recommended exclusion. Statistical validation was performed on remaining items. Spearman's rank analysis was used to investigate associations between damage scores and other disease status measures and Wilcoxon matched-pair analysis to assess sensitivity to change in the damage score. Results. Based on the expert validation, a 29-item damage score was agreed incorporating ocular, oral and systemic domains. Total damage score correlated with disease duration at study entry (r = 0.436; P < 0.001), physical function as measured by SF-36 (r = 0.250, T = 0 months; r = 0.261 T = 12 months) and activity as measured by the Sjögren's Systemic Clinical Activity Index (r = 0.213, T = 0 months; r = 0.215, T =12 months). Ocular damage score correlated with the ‘eye dry’ domain of PROFAD-SSI (r = 0.228, T = 0 months; r = 0.365, T = 12 months). Other associations not present on both assessments were considered clinically insignificant. On Wilcoxon analysis, the index was sensitive to change over 12 months (z = −3.262; P < 0.01). Conclusion. This study begins validation of a tool for collection of longitudinal damage data in PSS. We recommend further trial in both the experimental and clinical environment.Keywords
This publication has 12 references indexed in Scilit:
- Sjogren's Systemic Clinical Activity Index (SCAI) a systemic disease activity measure for use in clinical trials in primary Sjogren's syndromeRheumatology, 2007
- Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patientsArthritis & Rheumatism, 2007
- Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire toolRheumatology, 2004
- Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals Of The Rheumatic Diseases, 2002
- Revisiting Sjogren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UKRheumatology, 2001
- Clinical evolution, and morbidity and mortalityof primary Sjögren's syndromeSeminars in Arthritis and Rheumatism, 2000
- The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus ErythematosusArthritis & Rheumatism, 1997
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996
- Long‐term followup of patients with Sjögren's syndromeArthritis & Rheumatism, 1996
- Increased Risk of Lymphoma in Sicca SyndromeAnnals of Internal Medicine, 1978